Key facts
- This page summarizes Gerald E. Quirk's Form 4 filing for Syros Pharmaceuticals, Inc. (SYRS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 Oct 2022, 16:20.
Gerald E. Quirk - 11 Oct 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)
- Reporting relationship
- Chief Legal Officer
- Issuer ticker
- SYRS
- Reported as of
- 11 Oct 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Oct 2022, 16:20:07 UTC
- Next SEC filing
- 14 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Todd Rosenthal, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gerald E. Quirk filed Form 4 for Syros Pharmaceuticals, Inc. (SYRS) on 13 Oct 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SYRS
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +45,000
- Change %
- Price
- $0.000000
- Shares after
- 45,000
- Date
- 11 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 45,000
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
Footnote F2
These RSUs will vest as to one half (50%) of the shares on October 11, 2023, and as to one half (50%) of the shares on March 31, 2024.